We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.15 | 0.15% | 97.65 | 1,190 | 13:39:28 |
By Alberto Delclaux
Novartis AG (NOVN.EB) said Monday that its drug Tasigna secured European Union approval for first and second-line treatment of Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase, or Ph+ CML-CP, in children.
It means Tasigna is the only second-generation tyrosine kinase inhibitor currently approved in the EU for this treatment in children, Novartis said. The approval follows a positive opinion issued on Sep. 14 by the European Medicines Agency's Committee for Medicinal Products for Human Use.
Chronic Myeloid Leukemia, or CML, is responsible for approximately 10% to 15% of all adult cases of Leukemia, with an incidence of one to two cases per 100,000 a year, Novartis said. Almost all patients with CML have an abnormality known as the Philadelphia chromosone it added.
Write to Alberto Delclaux at alberto.delclaux@dowjones.com
(END) Dow Jones Newswires
November 20, 2017 02:18 ET (07:18 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions